DHBUD
Delivra Health Brands Inc., through its subsidiaries, provides lifestyle, health, and wellness products to consumers and patients worldwide. The company offers cannabis, liquid sleep shots, sleep powder packets, gummies, and pain relief creams. It sells its products under LivRelief, Dream Water, and LivRelief infused brands. The company was formerly known as Harvest One Cannabis Inc. Delivra Heal… Read more
DHBUD (DHBUD) - Net Assets
Latest net assets as of March 2025: $4.21 Million USD
Based on the latest financial reports, DHBUD (DHBUD) has net assets worth $4.21 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.61 Million) and total liabilities ($4.40 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.21 Million |
| % of Total Assets | 48.9% |
| Annual Growth Rate | -19.55% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 48.88 |
DHBUD - Net Assets Trend (2021–2024)
This chart illustrates how DHBUD's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for DHBUD (2021–2024)
The table below shows the annual net assets of DHBUD from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | $5.19 Million | +53.26% |
| 2023-06-30 | $3.39 Million | +0.47% |
| 2022-06-30 | $3.37 Million | -66.19% |
| 2021-06-30 | $9.98 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to DHBUD's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 631700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $174.36 Million | 3356.87% |
| Total Equity | $5.19 Million | 100.00% |
DHBUD Competitors by Market Cap
The table below lists competitors of DHBUD ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shadman Cotton Mills Limited
KAR:SHCM
|
$1.23K |
|
AZUL4F
SA:AZUL4F
|
$1.23K |
|
JFEN3F
SA:JFEN3F
|
$1.24K |
|
Thoresen Thai Agencies PCL
STU:NYVU
|
$1.24K |
|
Chinawe.com Inc
PINK:CHWE
|
$1.23K |
|
Vergnet
PA:ALVER
|
$1.23K |
|
B.R.R Guardian Ltd.
KAR:BRRG
|
$1.23K |
|
Croma Security Solutions Group Plc
LSE:CSSG
|
$1.22K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DHBUD's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,389,000 to 5,194,000, a change of 1,805,000 (53.3%).
- Net income of 876,000 contributed positively to equity growth.
- New share issuances of 819,000 increased equity.
- Other factors increased equity by 110,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $876.00K | +16.87% |
| Share Issuances | $819.00K | +15.77% |
| Other Changes | $110.00K | +2.12% |
| Total Change | $- | 53.26% |
Book Value vs Market Value Analysis
This analysis compares DHBUD's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.43x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.31x to 7.43x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-06-30 | $0.39 | $0.12 | x |
| 2022-06-30 | $0.01 | $0.12 | x |
| 2023-06-30 | $0.01 | $0.12 | x |
| 2024-06-30 | $0.02 | $0.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DHBUD utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.87%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.08%
- • Asset Turnover: 1.23x
- • Equity Multiplier: 1.94x
- Recent ROE (16.87%) is above the historical average (-120.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -286.04% | -358.70% | 0.42x | 1.91x | $-29.54 Million |
| 2022 | -207.80% | -86.12% | 0.70x | 3.43x | $-7.35 Million |
| 2023 | -5.43% | -1.88% | 0.93x | 3.12x | $-522.90K |
| 2024 | 16.87% | 7.08% | 1.23x | 1.94x | $356.60K |
Industry Comparison
This section compares DHBUD's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DHBUD (DHBUD) | $4.21 Million | -286.04% | 1.04x | $1.23K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |